MARKET COMPOSITE
LQDA - Liquidia Corp8:00:00 PM 3/28/2024
Price
$14.75
-0.32 (-2.12%)
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue4.5MM+23%
Gross Profit3.5MM-
Cost Of Revenue993K+74%
Operating Income-26.4MM+78%
Operating Expenses30MM-
Net Income-27.4MM+74%
R&D12.8MM+72%
G&A17.1MM+62%
Amortization300K-
Interest Expense2MM+11%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news